Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting

Impact · against what's priced in

Pharvaris has a concrete catalyst date for its Phase 3 CHAPTER-3 data, which is the primary driver for potential FDA approval and future revenue. While the presentation itself is a procedural step, the timing crystallizes the window for the stock's next major valuation shift.

Scored by the NIS engine · methodology.

• clinical trials▲8%
• biotech